Finance

Lists
LUNB:VIE
H Lundbeck A/S Class B
€5.84
-1.19%
(-0.070) 1D
Sep 7, 5:36:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LUNB...
Open
€5.89
High
€5.89
Low
€5.84
Mkt. cap
43.88B
Avg. vol.
1.00
Volume
0.00
52-wk high
€6.40
52-wk low
€4.85
No. of employees
5K
Open
€5.89
High
€5.89
Low
€5.84
Mkt. cap
43.88B
Avg. vol.
1.00
Volume
0.00
52-wk high
€6.40
52-wk low
€4.85
No. of employees
5K
Profile
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine. Wikipedia
About H Lundbeck A/S Class B
CEOCharl Van Zyl
Employees5K
FoundedAug 14, 1915
Headquarters-
SectorPharmaceutical industry
Websitelundbeck.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6.28B
6.09B
7.12B
6.46B
Cost of goods sold
846.00M
1.24B
1.30B
1.27B
Cost of revenue
846.00M
1.24B
1.30B
1.27B
Research and development expenses
1.16B
820.00M
1.38B
1.43B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.15B
2.54B
2.13B
2.28B
Operating expense
3.31B
4.36B
3.52B
3.70B
Total operating expenses
4.16B
5.60B
4.82B
4.96B
Operating income
2.12B
490.00M
2.31B
1.50B
Other non operating income
-
-32.00M
-
-
EBT including unusual items
1.41B
360.00M
2.13B
1.47B
EBT excluding unusual items
1.90B
567.00M
2.28B
1.47B
Income tax expense
311.00M
387.00M
468.00M
323.00M
Effective tax rate
22.03%
107.50%
22.01%
21.96%
Other operating expenses
-
997.00M
-
-11.00M
Net income
1.10B
-27.00M
1.66B
1.15B
Net profit margin
17.53%
-0.44%
23.27%
17.76%
Earnings per share
1.44
0.94
2.16
1.54
Interest and investment income
-
199.00M
-
-
Interest expense
-219.00M
-83.00M
-29.00M
-27.00M
Net interest expenses
-219.00M
116.00M
-29.00M
-27.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.55B
956.00M
2.78B
1.98B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps